GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharos IBio Co Ltd (XKRX:388870) » Definitions » EV-to-FCF

Pharos IBio Co (XKRX:388870) EV-to-FCF : -33.12 (As of Jun. 03, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Pharos IBio Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Pharos IBio Co's Enterprise Value is ₩142,212.44 Mil. Pharos IBio Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-4,294.33 Mil. Therefore, Pharos IBio Co's EV-to-FCF for today is -33.12.

The historical rank and industry rank for Pharos IBio Co's EV-to-FCF or its related term are showing as below:

XKRX:388870' s EV-to-FCF Range Over the Past 10 Years
Min: -79.21   Med: -12.65   Max: -8.63
Current: -31.49

During the past 5 years, the highest EV-to-FCF of Pharos IBio Co was -8.63. The lowest was -79.21. And the median was -12.65.

XKRX:388870's EV-to-FCF is ranked worse than
100% of 378 companies
in the Biotechnology industry
Industry Median: 8.345 vs XKRX:388870: -31.49

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-03), Pharos IBio Co's stock price is ₩12720.00. Pharos IBio Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-592.386. Therefore, Pharos IBio Co's PE Ratio for today is At Loss.


Pharos IBio Co EV-to-FCF Historical Data

The historical data trend for Pharos IBio Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharos IBio Co EV-to-FCF Chart

Pharos IBio Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- - - - -20.13

Pharos IBio Co Quarterly Data
Mar22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial - - -34.17 -20.13 -51.20

Competitive Comparison of Pharos IBio Co's EV-to-FCF

For the Biotechnology subindustry, Pharos IBio Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharos IBio Co's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharos IBio Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Pharos IBio Co's EV-to-FCF falls into.



Pharos IBio Co EV-to-FCF Calculation

Pharos IBio Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=142212.443/-4294.331
=-33.12

Pharos IBio Co's current Enterprise Value is ₩142,212.44 Mil.
Pharos IBio Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-4,294.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharos IBio Co  (XKRX:388870) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Pharos IBio Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=12720.00/-592.386
=At Loss

Pharos IBio Co's share price for today is ₩12720.00.
Pharos IBio Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-592.386.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Pharos IBio Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Pharos IBio Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharos IBio Co (XKRX:388870) Business Description

Traded in Other Exchanges
N/A
Address
427beon-gil, Dongan-gu, 1407 and 1408, 38, Heungan-daero, Seongji Star With, Gyeonggi-do, Gwanyang-dong, Anyang-si, KOR
Pharos IBio Co Ltd is a company specializing in new drug development that develops treatments for rare and intractable diseases. It utilizes a new drug development platform based on big data and AI technology. Its product candidate comprises PHI-101-AML, a treatment drug for refractory/relapsed acute myeloid leukemia; PHI-101-OC developed for platinum-resistant/refractory ovarian cancer patients; PHI-101-TNBC is being developed as a drug to treat metastatic triple-negative breast cancer (TNBC); PHI-201; PHI-301; and PHI-501.

Pharos IBio Co (XKRX:388870) Headlines

No Headlines